Immunovant, Inc. (IMVT) Financials

IMVT Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 852.5 million 117.1 million
March 31, 2026 957.0 million 104.4 million
Dec. 31, 2025 1.1 billion 66.3 million
Sept. 30, 2025 583.0 million 63.3 million

IMVT Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -124.4 million 13.8 million
March 31, 2026 -95.1 million 11.1 million
Dec. 31, 2025 -92.3 million 12.7 million
Sept. 30, 2025 -102.5 million 13.4 million

IMVT Net Income

No data available :(

IMVT Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 797.8 million - -
March 31, 2026 902.1 million - 72000
Dec. 31, 2025 994.5 million - -
Sept. 30, 2025 521.9 million - -

IMVT Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 205.5 million
March 31, 2026 203.7 million
Dec. 31, 2025 181.5 million
Sept. 30, 2025 173.6 million

IMVT Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 142.6 million 17.7 million -
March 31, 2026 8000 142.3 million 17.3 million -
Dec. 31, 2025 - 98.9 million 15.4 million -
Sept. 30, 2025 - 114.2 million 17.5 million -

IMVT Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 7.1 million -
March 31, 2026 - -
Dec. 31, 2025 - 101000
Sept. 30, 2025 - 105000

IMVT

Price: $41.82

52 week price:
14.32
42.62

Earnings Per Share: -2.93 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 791496

Market Capitalization: 8.8 billion

Links: